Shinkichi Takamori1, Gouji Toyokawa2, Isamu Okamoto3, Kazuki Takada4, Fumihiko Kinoshita1, Yuka Kozuma1, Taichi Matsubara1, Naoki Haratake1, Takaki Akamine1, Nobutaka Mukae5, Fumihiko Hirai1, Tetsuzo Tagawa1, Yoshinao Oda6, Toru Iwaki7, Koji Iihara5, Yoichi Nakanishi3, Yoshihiko Maehara1. 1. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Higashi, Fukuoka, Japan. 2. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Higashi, Fukuoka, Japan gouji104kawa@gmail.com. 3. Research Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyushu University, Higashi, Fukuoka, Japan. 4. Department of Thoracic Oncology, National Kyushu Cancer Center, Minami, Fukuoka, Japan. 5. Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Higashi, Fukuoka, Japan. 6. Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Higashi, Fukuoka, Japan. 7. Department of Neuropathology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Higashi, Fukuoka, Japan.
Abstract
AIM: To investigate the association between positivity for programmed cell death-ligand 1 (PD-L1) in brain metastases (BM) and the prognosis or clinical factors in patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Thirty-two patients with surgically resected brain-metastatic NSCLC were enrolled. The PD-L1 expression in BM was analyzed using the antibody against human PD-L1 (clone SP142). The PD-L1 positivity was defined as PD-L1 expression on brain-metastatic tumor cells of ≥5%. RESULTS: Seven (21.9%) out of 32 patients showed PD-L1 positivity in BM. The PD-L1-positive BM group had a significantly shorter brain-specific disease-free survival than the PD-L1-negative BM group (p<0.05). PD-L1 positivity in BM was significantly associated with a heavy smoking history and the administration of radiotherapy for BM before surgery (p<0.05 and p<0.05, respectively). CONCLUSION: The PD-L1 expression in BM from NSCLC may be associated with local recurrence following surgery, and the smoking- or radiotherapy-derived effects. Copyright
AIM: To investigate the association between positivity for programmed cell death-ligand 1 (PD-L1) in brain metastases (BM) and the prognosis or clinical factors in patients with non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Thirty-two patients with surgically resected brain-metastatic NSCLC were enrolled. The PD-L1 expression in BM was analyzed using the antibody against humanPD-L1 (clone SP142). The PD-L1 positivity was defined as PD-L1 expression on brain-metastatic tumor cells of ≥5%. RESULTS: Seven (21.9%) out of 32 patients showed PD-L1 positivity in BM. The PD-L1-positive BM group had a significantly shorter brain-specific disease-free survival than the PD-L1-negative BM group (p<0.05). PD-L1 positivity in BM was significantly associated with a heavy smoking history and the administration of radiotherapy for BM before surgery (p<0.05 and p<0.05, respectively). CONCLUSION: The PD-L1 expression in BM from NSCLC may be associated with local recurrence following surgery, and the smoking- or radiotherapy-derived effects. Copyright
Authors: Michael Zhang; Adrian J Rodrigues; Erqi L Pollom; Iris C Gibbs; Scott G Soltys; Steven L Hancock; Joel W Neal; Sukhmani K Padda; Kavitha J Ramchandran; Heather A Wakelee; Steven D Chang; Michael Lim; Melanie Hayden Gephart; Gordon Li Journal: J Neurooncol Date: 2021-01-07 Impact factor: 4.130
Authors: Yang Song; Ming Yang; Hongjian Zhang; Yan Sun; Ye Tao; Huihui Li; Jing Zhang; Yuncheng Li; Jianming Yang Journal: J Immunol Res Date: 2020-12-18 Impact factor: 4.818
Authors: Raees Tonse; Muni Rubens; Haley Appel; Martin C Tom; Matthew D Hall; Yazmin Odia; Michael W McDermott; Manmeet S Ahluwalia; Minesh P Mehta; Rupesh Kotecha Journal: Neurooncol Adv Date: 2021-11-10